Psychedelic Business Spotlight – June 17
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
Numinus Wellness
Psychedelic Business Spotlight – June 10
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
Psychedelic Business Spotlight – May 20
This week in psychedelic business news: Another psychedelic merger; an Optimi Health acquisition; and good news for alcohol abuse treatment.
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
Psychedelic Business Spotlight – April 15
This week in psychedelic business news: The industry’s first major merger; NeonMind launches clinics; a portfolio of patents is acquired.
Numinus Acquiring Novamind in First Major Psychedelics Merger
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic Business Spotlight – February 4
Levitee Labs Announces Interim CEO and Board of Directors Shuffle…
Health Canada Grants Special Access to Restricted Drugs for Psychedelic Therapy
New amendment reverses a 2013 Health Canada policy that prevented “a letter of authorization for a new drug that is or that contains a restricted drug.”
Psychedelic Business Spotlight: December 3
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Psychedelic Business Spotlight: November 12
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
End of content
End of content